NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/21/2025
Back to search
Official data from USPTO
NATCO PHARMA USA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
NATCO PHARMA USA
ST13
US500000098518715Class
5
Filing
98518715
Registration
7662429
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
13
Latest update
01/21/2025
Trademark type
Word
Nice classes
5
Filing date
04/25/2024
Registration date
01/21/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/21/2025
Last transaction
01/21/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
First use anywhere
03/08/2024
First use in commerce
03/08/2024
Drawing code
4
Owner type
16
Owner location
Parsippany, NJ
Examiner
KON, ELISSA
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Natco Pharma USA LLC
Representatives
Michael A. Marrero UB Greensfelder LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
allergy medications; anticonvulsants; anti-constipation medicines; anti-fungals; antihistamines; cough suppressants; cough-treatment medicines; expectorants; irritable-bowel-syndrome treatment preparations; laxatives; medicated mouthwash; medicated mouthwash for the treatment of gingivitis; medicines for alleviating constipation; milk of magnesia; nausea treatment preparations; stool softeners; ulcer medicines; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for the treatment of sleep apneanarcolepsyshift-work sleep disorders; pharmaceutical products for the treatment of cancer; pharmaceutical products for treating respiratory diseases; pharmaceutical preparations for the treatment of nausea and vomiting from cancer-related chemotherapyradiationsurgery; pharmaceutical preparations for the treatment of anxiety disorders; pharmaceutical preparations for the treatment of stomach painbloatingstraining; pharmaceutical preparations for the treatment of seizures related to epilepsy; pharmaceutical preparations for the treatment of chest congestion; pharmaceutical preparations for the treatment of angina pectoris and chronic heart failurenitroglycerin
Publications
History of USPTO decisions and trademark events.
13 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/21/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/03/2024
PUBO
PUBLISHED FOR OPPOSITION
12/03/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/27/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/12/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
11/12/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/12/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
11/12/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/12/2024
DOCK
ASSIGNED TO EXAMINER
11/08/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/25/2024
NWAP
NEW APPLICATION ENTERED
04/25/2024
Continuous trademark protection
Get notified about every new filing that threatens NATCO PHARMA USA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.